3 Things About DermTech That Smart Investors Know

DermTech (NASDAQ: DMTK), a company that is trying to redefine testing for skin cancer, has been a sleeper stock for the better half of 2021. The company has created a patch that makes testing for skin cancer easier and more accurate, yet the stock has fallen 60% from its February highs.

With the stock reaching prices near its all-time lows, investors are eyeing this company as one to buy today. However, this discount in the share price does not mean it is a buy now; there are a lot of things this company has to do right for many years for it to become a less risky stock. Here are three things smart investors know before investing in this innovative company.

Image source: Getty Images

Source Fool.com